
Robert Battat

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5947284/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global health competencies and approaches in medical education: a literature review. BMC Medical Education, 2010, 10, 94.	1.0	191
2	Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1427-1434.e2.	2.4	187
3	Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: Systematic review and meta-analysis. Digestive and Liver Disease, 2017, 49, 854-863.	0.4	101
4	Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology, 2016, 28, 1137-1144.	0.8	87
5	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1031-1038.	1.9	80
6	Vitamin B12 Deficiency in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 1.	0.9	78
7	Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, e361-e379.	2.4	68
8	Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World Journal of Gastroenterology, 2016, 22, 7727.	1.4	65
9	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology, 2020, 158, 515-526.e10.	0.6	65
10	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2018, 16, 129-146.	0.3	64
11	Management of inflammatory bowel disease with <i>Clostridium difficile</i> infection. World Journal of Gastroenterology, 2017, 23, 4986.	1.4	62
12	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology, 2021, 160, 2291-2302.	0.6	57
13	Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs, 2019, 79, 1321-1335.	4.9	51
14	Risk Factors Associated with <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Crohn's and Colitis, 2019, 13, 27-38.	0.6	49
15	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2019, 114, 733-745.	0.2	42
16	Systematic review with metaâ€analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2019, 50, 848-857.	1.9	40
17	Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 319-330.	1.4	37
18	Practice guidelines for endoscopic ultrasound-guided celiac plexus neurolysis. Endoscopic Ultrasound, 2017, 6, 369.	0.6	37

ROBERT BATTAT

#	Article	lF	CITATIONS
19	Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2017, 62, 2982-2990.	1.1	36
20	Machine learning models and over-fitting considerations. World Journal of Gastroenterology, 2022, 28, 605-607.	1.4	34
21	Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2019, 17, 127-145.	0.3	30
22	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 410-420.	0.9	28
23	Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 511-518.e6.	2.4	28
24	Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2722-2730.e4.	2.4	26
25	Hematologic Indices as Surrogate Markers for Monitoring Thiopurine Therapy in IBD. Digestive Diseases and Sciences, 2015, 60, 478-484.	1.1	23
26	A product review of vedolizumab in inflammatory bowel disease. Human Vaccines and Immunotherapeutics, 2019, 15, 2482-2490.	1.4	20
27	Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterology, 2021, 8, e000774.	1.1	20
28	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101602.	1.0	19
29	Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 1436-1449.	2.4	19
30	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1443-1451.	0.9	18
31	Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. Drug Safety, 2019, 42, 617-632.	1.4	17
32	The Haiti Medical Education Project: development and analysis of a competency based continuing medical education course in Haiti through distance learning. BMC Medical Education, 2016, 16, 275.	1.0	16
33	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. American Journal of Gastroenterology, 2020, 115, 885-894.	0.2	15
34	Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study. European Journal of Gastroenterology and Hepatology, 2017, 29, 1361-1367.	0.8	12
35	No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. Clinical Gastroenterology and Hepatology, 2021, 19, 2312-2314.e3.	2.4	12
36	Defining theÂphenotype, pathogenesis and treatment of Crohn's diseaseÂassociated spondyloarthritis. Journal of Gastroenterology, 2020, 55, 667-678.	2.3	9

ROBERT BATTAT

#	Article	IF	CITATIONS
37	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, 224-243.	0.6	9
38	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097121.	1.4	7
39	Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study. Frontiers in Medicine, 2021, 8, 801532.	1.2	7
40	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 1574-1582.	1.9	5
41	Endoscopist-Directed Propofol as an Adjunct to Standard Sedation: A Canadian Experience. Journal of the Canadian Association of Gastroenterology, 2020, 3, 141-144.	0.1	4
42	A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2021, Publish Ahead of Print, e176-e182.	1.1	4
43	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. Current Treatment Options in Gastroenterology, 2020, 18, 15-32.	0.3	3
44	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 3563-3569.	1.1	3
45	Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index. Crohn's & Colitis 360, 2021, 3, .	0.5	3
46	Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease. Inflammatory Bowel Diseases, 2022, 28, 1865-1871.	0.9	3
47	Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived?. Journal of Crohn's and Colitis, 0, , .	0.6	3
48	Editorial: calcineurin inhibitors as a bridge to vedolizumab for severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 663-664.	1.9	2
49	Tu1835 – Association Between Vedolizumab Trough Concentration and Clinical Outcomes in Patients with Inflammatory Bowel Diseases: Implications for Clinical Practice. Gastroenterology, 2019, 156, S-1143.	0.6	1
50	Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data. American Journal of Gastroenterology, 2021, 116, 2029-2031.	0.2	1
51	S0783 Markedly Elevated 7-α-hydroxy-4-cholesten-3-one (C4) Is Associated With Fat Malabsorption in the Setting of Short Bowel Syndrome. American Journal of Gastroenterology, 2020, 115, S400-S400.	0.2	1
52	Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn's Disease. Journal of Clinical Gastroenterology, 2022, 56, e166-e170.	1.1	1
53	Reply to Letter on: â€~Risk Factors Associated With <i>Clostridium difficile</i> Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis'. Journal of Crohn's and Colitis, 2019, 13, 536-537.	0.6	0
54	Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 568-569.	1.9	0

#	Article	IF	CITATIONS
55	Therapeutic Drug Monitoring of Certolizumab Pegol: Can Real-World Data Translate to Clinical Practice?. Crohn's & Colitis 360, 2021, 3, .	0.5	Ο
56	Authors' Reply to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease― Inflammatory Bowel Diseases, 2022, 28, e61-e61.	0.9	0